中慧生物的四价流感病毒亚单位疫苗上市申请获批

Core Viewpoint - Zhonghui Biotech has received approval from the National Medical Products Administration for its quadrivalent influenza virus subunit vaccine aimed at the population aged 6 to 35 months, marking it as the first and only approved quadrivalent influenza virus subunit vaccine for the entire population in China [1] Company Summary - Zhonghui Biotech announced the approval of its new drug application for a quadrivalent influenza virus subunit vaccine [1] - The vaccine is specifically designed for children aged 6 to 35 months [1] - This vaccine is notable for being the first and only one approved for the entire population in China [1]